The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IMAGING BIOMETRICS ANNOUNCES PARTNERSHIP

11 Apr 2018 07:00

RNS Number : 4904K
Flying Brands Limited
11 April 2018
 

 

 

FLYING BRANDS' SUBSIDIARY IMAGING BIOMETRICS ANNOUNCES DISTRIBUTION PARTNERSHIP WITH AI EXCHANGE PLATFORM, ENVOY AI

 

IB Neuro and IB Delta T1 Maps are now available on EnvoyAI's artificial intelligence Exchange

 

 

Flying Brand's newly acquired subsidiary Imaging Biometrics®, LLC ("IB"), a medical imaging software company specialising in advanced visualisation and analytics, has entered into a distribution agreement with EnvoyAI, a leading artificial intelligence ("AI") Exchange platform. IB Neuro, the premier magnetic resonance ("MR") imaging dynamic susceptibility contrast (DSC) perfusion solution, and IB's Delta T1 mapping algorithm, are now available for purchase on the EnvoyAI Exchange.

 

Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI said, "We recently added Imaging Biometrics' FDA cleared post-processing solutions to the EnvoyAI Exchange. The proprietary quantitative and automated algorithms contained in IB Neuro and IB Delta Suite provide clinicians with incredible value by producing unique imaging biomarkers that enable them to accurately monitor treatment response in brain tumor patients."

 

"This partnership with EnvoyAI enables immediate and widespread access to our proven and quantitative imaging biomarkers for neuro radiologists, neuro-oncologist, and neuro surgeons," said Michael Schmainda, CEO of IB. "The need to accurately quantify changes in brain tumor patients is becoming more important and yet increasingly difficult due to the challenging side effects of newer therapies and cancer fighting agents. The exclusive technology contained in IB's products overcome these difficulties and, through the unique additional information made available, aid the treatment team's ability to rapidly and objectively assess whether patients are responding to treatment. We are delighted to participate on the EnvoyAI Exchange and look forward to providing sophisticated imaging solutions to benefit clinicians and their patients."

 

About EnvoyAI (www.envoyai.com)

EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialisation processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

About Imaging Biometrics® LLCImaging Biometrics develops and provides visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

 

About Flying Brands PLC

Flying Brands PLC (Ticker:FBDU) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.flyingbrands.co.uk).

The Directors of Flying Brands Limited accept responsibility for the contents of this announcement.

 

 **ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

 

Peterhouse Corporate Finance (Financial Adviser and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRKMGMDVGGGRZM
Date   Source Headline
9th Nov 20207:00 amRNSIB and the Mayo Clinic enter into an Agreement
6th Nov 20204:35 pmRNSPrice Monitoring Extension
6th Nov 20202:05 pmRNSSecond Price Monitoring Extn
6th Nov 20202:00 pmRNSPrice Monitoring Extension
6th Nov 202011:05 amRNSSecond Price Monitoring Extn
6th Nov 202011:00 amRNSPrice Monitoring Extension
5th Nov 20204:41 pmRNSSecond Price Monitoring Extn
5th Nov 20204:36 pmRNSPrice Monitoring Extension
5th Nov 20209:00 amRNSPrice Monitoring Extension
5th Nov 20207:00 amRNSMontgomery Cancer Center Purchases IB's Software
4th Nov 20207:00 amRNSLSN Software Receives FDA Clearance
30th Oct 202011:05 amRNSSecond Price Monitoring Extn
30th Oct 202011:00 amRNSPrice Monitoring Extension
30th Oct 20207:00 amRNS"Gad Free" Imaging moves to Validation Testing
15th Oct 20207:00 amRNSIB Stroke
8th Oct 20203:41 pmRNSStoneChecker Update
24th Sep 202010:43 amRNSThe Benefits and Significance of IB Neuro
16th Sep 20207:00 amRNSKeck Medical Centre of USC Purchases IB's Software
10th Sep 20207:00 amRNSIB Trax™
4th Sep 20209:03 amRNS“Gad Free” Imaging - One Step Closer
7th Aug 20207:00 amRNSHalf-year Report
5th Aug 20204:41 pmRNSSecond Price Monitoring Extn
5th Aug 20204:35 pmRNSPrice Monitoring Extension
5th Aug 202011:05 amRNSSecond Price Monitoring Extn
5th Aug 202011:00 amRNSPrice Monitoring Extension
5th Aug 20209:53 amRNSStonechecker Update
27th Jul 20207:00 amRNSUpdate - IB Stroke
10th Jul 20207:00 amRNSNew Development Aims to Detect Tumor Infiltration
19th Jun 20207:00 amRNSIB, the Recognised National Standard in MRI DSC
15th Jun 202011:52 amRNSResult of AGM
1st Jun 20207:00 amRNSIB Awarded $2.57m grant
19th May 20209:19 amRNSNotice of AGM
4th May 202010:04 amRNSFinal Results
30th Apr 20201:08 pmRNSDelay in Publishing Final Year Accounts
18th Mar 20202:34 pmRNSIB's Software featured in award-winning article
3rd Mar 20204:40 pmRNSSecond Price Monitoring Extn
3rd Mar 20204:35 pmRNSPrice Monitoring Extension
28th Feb 20201:42 pmRNSTotal Voting Rights
5th Feb 20204:30 pmRNSConversion of Loan Notes - Correction
5th Feb 20203:20 pmRNSConversion of Loan Notes
27th Jan 20209:29 amRNSImaging Biometrics Adds to Development Team
20th Jan 20207:00 amRNSKFDA Clearance for StoneChecker Software
13th Jan 202011:35 amRNSExercise of Options
9th Jan 20207:00 amRNSImaging Biometrics Partners with AI Metrics
18th Dec 201912:46 pmRNSBoard Changes and Restructuring Initiatives
7th Nov 20197:01 amRNSInitiation of IB Stroke Project
2nd Oct 20192:00 pmRNSPrice Monitoring Extension
1st Oct 20192:05 pmRNSSecond Price Monitoring Extn
1st Oct 20192:00 pmRNSPrice Monitoring Extension
1st Oct 201911:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.